Syngene International liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
7.11×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.38×1.38×1.64×1.71×2.04×
1.29×1.29×1.53×1.50×1.76×
529685978599914
7655918918151,237
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹16,060 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————7.11
Current Ratio2.041.711.641.381.38
Quick Ratio1.761.501.531.291.29
Cash, Equiv & ST Investments913.9598.9977.6684.7529.2
Working Capital1,237.1814.7890.9590.5765.2
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.